ABOS

Acumen Pharmaceuticals, Inc.

• TipRanks·2d ago

  BTIG Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS)

• TipRanks·3d ago

  Acumen Pharmaceuticals’ Earnings Call: Promise Amid Pressure

• Seeking Alpha·03/27 13:50

  Acumen Pharmaceuticals files to sell 10.83M shares of common stock for holders

• Benzinga·03/27 12:05

  12 Health Care Stocks Moving In Friday's Pre-Market Session

• Seeking Alpha·03/26 22:26

  Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding

• Benzinga·03/26 20:44

  Acumen Pharmaceuticals Files Prospectus To Resell Up To 10,833,331 Shares From March 16, 2026 Private Placement

• TipRanks·03/26 20:35

  Acumen files to sell 10.83M shares of common stock for holders

• Reuters·03/26 20:30

  ACUMEN PHARMACEUTICALS INC - FILES FOR OFFERING OF UP TO 10,833,331 COMMON SHARES BY THE SELLING STOCKHOLDERS - SEC FILING

• Dow Jones·03/26 16:43

  Acumen Pharmaceuticals Price Target Maintained With a $8.00/Share by BTIG

• Benzinga·03/26 16:32

  BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target

• Benzinga·03/26 12:23

  Acumen Pharmaceuticals Q4 EPS $(0.41) Beats $(0.43) Estimate

• Reuters·03/26 12:07

  Acumen Pharmaceuticals publishes corporate presentation; Alzheimer’s drug candidate sabirnetug advances in Phase 2, cash totals $117 million at Dec. 31, 2025

• TipRanks·03/26 12:05

  Options Volatility and Implied Earnings Moves Today, March 26, 2026

• TipRanks·03/26 11:30

  Acumen Updates Alzheimer’s Pipeline, Extends Cash Runway Into 2027

• Seeking Alpha·03/26 11:23

  Acumen Pharmaceuticals GAAP EPS of -$2.00 beats by $0.02